분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-03-24 23:54:04 , Hit : 2020
 J&J-Medivir Drug for Hepatitis C Recommended by EU Regulator


Bloomberg News



By Makiko Kitamura   March 21, 2014


Johnson & Johnson (JNJ:US) and Medivir AB (MVIRB)’s pill to treat chronic hepatitis was recommended for approval by the European Union’s drug regulator.

The medicine, known as simeprevir, was recommended by a European Medicines Agency panel as a treatment for chronic hepatitis C in adult patients, the regulator said in a statement today. The drug was approved by the U.S. Food and Drug Administration in November. If backed by the European Commission, the pill would be marketed as Olysio.

J&J, Medivir, Gilead Sciences Inc. and Bristol-Myers Squibb Co. (BMY:US) are among companies that have been developing new pills for the virus that reduce the need for interferon shots, which cause flu-like symptoms. The market for hepatitis C drugs may reach more than $100 billion over a decade, according to Bloomberg Industries. Simeprevir may generate $326 million (JNJ:US) for New Brunswick, New Jersey-based J&J in 2016, according to the average of four analysts’ estimates compiled by Bloomberg.

Story: Did the State Department Fail Obama on Keystone XL?

Gilead’s hepatitis C treatment Sovaldi was cleared by the FDA in December. While simeprevir can cut the current treatment time in half to 24 weeks, Sovaldi works in 12 weeks for most patients.

AbbVie Inc. (ABBV:US) is also developing a 12-week combination treatment that cured 99 percent of patients in a late-stage trial, the company said this month.

Hepatitis C, which affects 150 million people globally, can be passed through infected blood or body fluids, commonly through needle-sharing by drug users. The virus may be carried for years without symptoms, and the U.S. Centers for Disease Control and Prevention has recommended that baby boomers born between 1945 and 1965 get tested for the infection.

Story: Andrew Hessel's Autodesk Team Seeks Crowdsourced Cancer Cure

The European agency’s recommendations are the final stage before the European Commission, the EU’s executive arm, approves or rejects a drug for sale to patients in the 28-nation region.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editors responsible for this story: Phil Serafino at pserafino@bloomberg.net Kristen Hallam, Robert Valpuesta







847   CRISPR Reverses Disease Symptoms in Living Animals for First Time  이성욱 2014/04/01 1687
846   약물 생산을 보다 저렴하고 환경친화적으로 만드는데 도움을 주는 바이오 역합성  이성욱 2014/03/26 2114
  J&J-Medivir Drug for Hepatitis C Recommended by EU Regulator  이성욱 2014/03/24 2020
844   스트레스를 받는 뇌세포는 알츠하이머로부터 보호작용을 한다  이성욱 2014/03/24 1930
843   RNA 치료제 등 3대 R&D 트렌드  이성욱 2014/03/18 2017
842   막다른 골목에 몰린 STAP 세포  이성욱 2014/03/18 1933
841   암 세포의 혈관 밖 이동을 돕는 자외선  이성욱 2014/03/13 2167
840   유전자 편집방법을 이용한 HIV 치료  이성욱 2014/03/10 2085
839   Merck hepatitis C drugs work in HIV co-infected patients -study  이성욱 2014/03/08 1731
838   Gene Therapy for Controlling HIV Shows Early Promise  이성욱 2014/03/08 1661
837   Fragile X syndrome: Trigger for most common form of intellectual disability and autism uncovered  이성욱 2014/03/05 1819
836   인체 '게놈 분석 1000달러 시대' 왔다  이성욱 2014/02/28 2112
835   FDA Gives Bristol-Myers' Hepatitis Drug 'Breakthrough' Designation  이성욱 2014/02/26 2040
834   숙주 세포 핵의 바아러스 DNA 분해  이성욱 2014/02/26 2276
833   Genetically Altered Stem Cells Generate Engineered Cartilage  이성욱 2014/02/22 2108
832   자궁경부암 유발 바이러스에도 효과를 보이는 HIV 약물  이성욱 2014/02/21 2407
831   美 연구팀, ‘원숭이 아바타’ 실험 성공시켰다  이성욱 2014/02/20 2129
830   Small non-coding RNAs could be warning signs of cancer  이성욱 2014/02/18 1814
829   Gilead submits fixed-dose combination ledipasvir/sofosbuvir HCV tablet for FDA approval  이성욱 2014/02/12 2388
828   Researchers turn adult cells back into stem cells  이성욱 2014/01/30 1665

[이전 10개] [1]..[21] 22 [23][24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN